Compare UPC & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UPC | PPCB |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | China | Australia |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.9M |
| IPO Year | 2020 | N/A |
| Metric | UPC | PPCB |
|---|---|---|
| Price | $3.13 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.4K | ★ 1.2M |
| Earning Date | 01-30-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $0.10 |
| 52 Week High | $11.00 | $10.69 |
| Indicator | UPC | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 34.55 |
| Support Level | $2.66 | N/A |
| Resistance Level | $3.28 | $0.40 |
| Average True Range (ATR) | 0.26 | 0.01 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 87.45 | 21.67 |
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.